Results released Friday show itepekimab succeeded in one Phase 3 trial but failed in a second, sinking shares of both partner ...

The smart inhalers market is experiencing significant growth, driven by the increasing incidence of respiratory diseases like asthma and COPD, techno ...

We recently published a list of Jim Cramer Put These 14 Stocks Under the Microscope. In this article, we are going to take a ...

AERIFY-1 trial met the primary endpoint of a statistically significant reduction in moderate or severe exacerbations in former smokers rega ...

Long-term oxygen therapy (LTOT) is linked to reduced exacerbations and hospitalizations in COPD, ILD, and pulmonary hypertension.

Aspergillus, a potentially deadly fungus, is expanding its reach due to climate change, posing a significant threat to public ...

MUSC Health Florence Medical Center has spearheaded the introduction of an advanced aerosol delivery system – one that is now transforming how respiratory patients receive breathing treatments in ...

AERIFY-1 trial met the primary endpoint of a statistically significant reduction in moderate or severe exacerbations in former smokers regardless of eosinophilic phenotype and provided a clinically me ...

Partners Regeneron and Sanofi say itepekimab only achieved a significantly statistic result in one of two studies.

About itepekimab Itepekimab is a fully human monoclonal antibody that binds to and inhibits interleukin-33 (IL33), an initiator and amplifier of broad inflammation in COPD. IL33 is thought to be ...

Learn when your cough signals serious health problems beyond a cold. Duration, sound, and symptoms reveal hidden dangers.